Sign in
BBLG Stock Price, Chart, Stats & News
Bone Biologics Corporation
Save
Bone Biologics Corporation (BBLG) does not currently pay a dividend.
889,259
Market cap
–
Current P/E
–
Forward P/E
BBLG chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -53.64% |
ROE | -59.50% |
D/E | – |
Interest coverage ratio | – |
BBLG valuation
P/E | – |
P/S | – |
P/B | 0.24x |
P/CF | -0.48x |
P/FCF | -0.74x |
P/OCF | -0.48x |
PEG | 0.07x |
EV multiple | -2.36x |
About
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments.
Similar securities
Based on sector and market capitalization
Report issue